Literature DB >> 8917181

Four- to twenty-four-hour uptake ratio: an index of rapid iodine-131 turnover in hyperthyroidism.

R Aktay1, K Rezai, J E Seabold, R S Bar, P T Kirchner.   

Abstract

UNLABELLED: Rapid thyroidal iodine turnover may contribute to 131I therapy failure in patients with hyperthyroidism. The utility of a 4- to 24-hr 131I uptake ratio was evaluated as an index of thyroidal iodide retention in hyperthyroid patients.
METHODS: In 433 hyperthyroid patients, the success of 131I therapy was correlated with the following factors: gender, pretreatment with antithyroid drugs, clinical diagnosis, magnitude of early and late thyroidal 131I uptake values, and the 4- to 24-hr 131I uptake ratio.
RESULTS: Of the 433 patients, 362 patients (84%) had a successful outcome after a single therapeutic dose of 131I while 71 (16%) did not. Multiple linear regression analysis revealed that the highest statistically significant predictor of outcome was the 4- to 24-hr 131I uptake ratio (p-value < 0.001); all other factors showed a weaker association. An 131I uptake ratio of > 1 was found in 67 (15%) patients. Thirty-two of these 67 patients (48%) failed 131I therapy, whereas those patients with uptake ratios of < 1.0, only 39/366 (11%) failed 131I therapy.
CONCLUSION: The 4- to 24-hr 131I thyroidal uptake ratio is a practical substitute for exact determination of the effective half-life. It identifies patients who are likely to have a rapid 131I turnover without the need for extended thyroid uptake measurements. An 131I uptake ratio of > or = 1 was found in 15% of hyperthyroid patients and was associated with a near 50% 131I therapy failure rate.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8917181

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  8 in total

1.  Comparative analysis of radioactive iodine versus thyroidectomy for definitive treatment of Graves disease.

Authors:  Vincent T Wu; Allison W Lorenzen; Anna C Beck; Vincent J Reid; Sonia L Sugg; James R Howe; Janet H Pollard; Geeta Lal; Ronald J Weigel
Journal:  Surgery       Date:  2016-11-15       Impact factor: 3.982

2.  Success rate of radioactive iodine treatment for children and adolescent with hyperthyroidism.

Authors:  S Namwongprom; P Dejkhamron; K Unachak
Journal:  J Endocrinol Invest       Date:  2020-06-24       Impact factor: 4.256

3.  Is There Any Need for Adjusting 131I Activity for the Treatment of High Turnover Graves' Disease Compared to Normal Turnover Patients? Results from a Retrospective Cohort Study Validated by Propensity Score Analysis.

Authors:  Saurabh Arora; Chandrasekhar Bal
Journal:  Nucl Med Mol Imaging       Date:  2021-01-07

4.  Thyroid Isthmus Length and Iodine Turnover as Predictors of Successful Radioactive Iodine Therapy in Patients with Graves' Disease.

Authors:  Se Hee Park; Sena Hwang; Seunghee Han; Dong Yeob Shin; Eun Jig Lee
Journal:  Int J Endocrinol       Date:  2017-12-05       Impact factor: 3.257

5.  Analysis of risk factors of rapid thyroidal radioiodine-131 turnover in Graves' disease patients.

Authors:  Ruiguo Zhang; Jian Tan; Renfei Wang; Guizhi Zhang; Qiang Jia; Zhaowei Meng; Yueqian Zhang
Journal:  Sci Rep       Date:  2017-08-15       Impact factor: 4.379

6.  Finding the best effective way of treatment for rapid I-131 turnover Graves' disease patients: A randomized clinical trial.

Authors:  Siwaporn Thamcharoenvipas; Stephen J Kerr; Supatporn Tepmongkol
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

7.  Radioiodine treatment of hyperthyroidism: fixed or calculated doses; intelligent design or science?

Authors:  Johannes W van Isselt; John M H de Klerk; Cornelis J M Lips
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-11       Impact factor: 9.236

8.  Prediction of thyroidal 131I effective half-life in patients with Graves' disease.

Authors:  Ruiguo Zhang; Guizhi Zhang; Renfei Wang; Jian Tan; Yajing He; Zhaowei Meng
Journal:  Oncotarget       Date:  2017-09-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.